Acute Myeloid Leukemia Clinical Trial

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Summary

The purpose of this study was to compare relapse-free survival (RFS) between participants with FMS-like tyrosine kinase 3 (FLT3) / internal tandem duplication (ITD) acute myeloid leukemia (AML) in first complete remission (CR1) and who were randomized to receive gilteritinib or placebo beginning after completion of induction/consolidation chemotherapy for a two-year period.

View Full Description

Full Description

Participants in CR1 were approached for this study after induction/consolidation therapy was complete and a decision not to proceed with transplantation was made or a suitable donor could not be identified. Participants were randomized in a 2:1 ratio to receive gilteritinib or placebo. Participants entered the screening period up to 14 days prior to the start of treatment. Participants were administered treatment over continuous 28-day cycles. Gilteritinib or placebo was given daily for up to 2 years. After treatment discontinuation, participants had a 30-day follow-up visit for safety, after which the participants entered the long-term follow up period for collection of subsequent AML treatment, remission status, and survival (cause of death and date of death). Final database lock will occur when last subject last follow-up visit is reached, per protocol. Study drug was not provided during the follow-up period.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subject is considered an adult according to local regulation at the time of obtaining consent form (ICF).
Subject consents to allow access to subject's diagnostic bone marrow aspirate or peripheral blood sample and/or the DNA derived from that sample, if available, that may be used to validate a companion diagnostic test for gilteritinib.
Subject has confirmed morphologically documented AML, excluding acute promyelocytic leukemia (APL), in CR1 (including CRp and CRi). For the purposes of enrollment, CR will be defined as < 5% blasts in the bone marrow with no morphologic characteristics of acute leukemia (e.g., Auer rods) in the bone marrow with no evidence of extramedullary disease such as central nervous system involvement or granulocytic sarcoma.
Subject will not proceed with transplantation as either a decision not to proceed with transplantation has been made either on the recommendation of the treating physician or by the patient or a suitable donor could not be identified.
Subject is < 2 months from the start of the last cycle of consolidation and should have completed the recommended number of consolidations per local practice.
Subject has had no use of investigational agents, with the exception of FLT3 inhibiting agents during induction and/or consolidation therapy, within the prior 4 weeks.
Subject has had presence of the FLT3/ITD activating mutation in the bone marrow or peripheral blood as determined by the local institution at diagnosis.
Subject has an ECOG performance status 0 to 2.

Subject must meet the following criteria as indicated on the clinical laboratory tests:

Serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN), or if serum creatinine outside normal range, then glomerular filtration rate (GFR) > 40 mL/min/1.73m^2 as calculated with the 4-parameter Modification of Diet in Renal Disease (MDRD) equation.
Serum total bilirubin ≤ 2.5 mg/dL (43 μmol/L), except for subjects with Gilbert's syndrome.
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN.
Serum potassium and serum magnesium ≥ institutional lower limit of normal (LLN).
Absolute neutrophil count (ANC) ≥ 500/μl and platelets ≥ 20000/μl (unsupported by transfusions).
Subject is suitable for oral administration of study drug.

Female subject must either:

Be of nonchildbearing potential:
Postmenopausal (defined as at least 1 year without any menses) prior to screening, or
Documented surgically sterile or status posthysterectomy (at least 1 month prior to screening)
Or, if of childbearing potential,
Agree not to try to become pregnant during the study and for 6 months after the final study drug administration
And have a negative urine or serum pregnancy test at screening
And, if heterosexually active, agree to consistently use highly effective contraception per locally accepted standards (in addition to a barrier method) starting at screening and throughout the study period and for 6 months after the final study drug administration.
Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 2 months and 1 week after the final study drug administration.
Female subject must not donate ova starting at screening and throughout the study period, and for 6 months after the final study drug administration.
Male subject and subject's female partners who are of childbearing potential must be using highly effective contraception per locally accepted standards (in addition to a barrier method) starting at screening and continue throughout the study period and for 4 months and 1 week after the final study drug administration.
Male subject must not donate sperm starting at screening and throughout the study period and for 4 months and 1 week after the final study drug administration.
Subject agrees not to participate in another interventional study while on treatment.

Exclusion Criteria:

Subject has had prior allogeneic transplant.
Subject has QTcF interval > 450 msec (average of triplicate determinations based on central reading).
Subject with Long QT Syndrome.
Subject with hypokalemia and hypomagnesemia at screening (defined as values below LLN).
Subject has clinically active central nervous system leukemia.
Subject is known to have human immunodeficiency virus infection.
Subject has active hepatitis B or C.
Subject has an uncontrolled infection. If a bacterial or viral infection is present, the subject must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to randomization. If a fungal infection is present, the subject must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to randomization.
Subject has progressing infection defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
Subject has uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, congestive heart failure New York Heart Association (NYHA) class 3 or 4 or subject has a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram or multigated acquisition (MUGA) scan performed within 1 month prior to study entry results in a left ventricular ejection fraction that is ≥ 45%.
Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP) 3A.
Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P-glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.
Subject requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
Subject has a serious medical or psychiatric illness likely to interfere with participation in this clinical study.
Subject has prior malignancies, except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed.
Subject has any condition which makes the subject unsuitable for study participation.

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 2

Estimated Enrollment:

98

Study ID:

NCT02927262

Recruitment Status:

Completed

Sponsor:

Astellas Pharma Global Development, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 56 Locations for this study

See Locations Near You

Site US10017
Gainesville Florida, 32610, United States
Site US10030
Jacksonville Florida, 32204, United States
Site US10012
Chicago Illinois, 60612, United States
Site US10025
Syracuse New York, 13210, United States
Site US10007
Portland Oregon, 97239, United States
Site US10029
Greenville South Carolina, 26615, United States
Site BR55002
Goiania Goias, 74605, Brazil
Site CA15001
Halifax Nova Scotia, B3H2Y, Canada
Site CA15003
Toronto Ontario, M5G 2, Canada
Site CZ42001
Ostrava-Poruba , 70852, Czechia
Site DK45002
Arhus Region Midtjylland, DK 80, Denmark
Site FR33004
Brest Finistere, 29609, France
Site FR33002
Tours cedex 01 Indre-et-Loire, 37044, France
Site FR33014
Vandoeuvre les Nancy Meurthe-et-Moselle, 54511, France
Site FR33007
Pierre-Benite Rhone, 69310, France
Site FR33001
Bayonne , 64100, France
Site FR33009
Mulhouse , 68070, France
Site FR33008
Nice Cedex 2 , 06189, France
Site DE49001
Duisburg Nordrhein-Westfalen, 47166, Germany
Site DE49008
Stuttgart , 70376, Germany
Site GR30010
Athens Attiki, 10676, Greece
Site GR30004
Thessaloniki Kentriki Makedonia, 57010, Greece
Site GR30009
Athens , , Greece
Site GR30007
Larissa , , Greece
Site HU36003
Nyiregyhaza Szabolcs-Szatmar-Bereg, H-440, Hungary
Site IL97205
Jerusalem Yerushalayim, 91031, Israel
Site IT39011
Milano Lombardia, 20141, Italy
Site IT39004
Castelfranco Veneto (TV) Treviso, 31033, Italy
Site IT39008
Bergamo , 24127, Italy
Site IT39005
Parma , , Italy
Site IT39010
Reggio Emilia , 42100, Italy
Site IT39002
Roma , 161, Italy
Site JP81018
Nagoya Aichi, , Japan
Site JP81025
Matsuyama Ehime, , Japan
Site JP81002
Yoshida-gun Fukui, , Japan
Site JP81024
Sapporo Hokkaido, , Japan
Site JP81012
Kobe Hyogo, , Japan
Site JP81004
Kanazawa Ishikawa, , Japan
Site JP81009
Yokohama Kanagawa, , Japan
Site JP81014
Sendai Miyagi, , Japan
Site JP81023
Shimotsuke Tochigi, , Japan
Site JP81011
Tachikawa Tokyo, , Japan
Site JP81010
Aomori , , Japan
Site JP81017
Okayama , , Japan
Site KR82005
Suwon-si Gyeonggi-do, 16499, Korea, Republic of
Site KR82014
Bucheon-Si Gyeonggido, 14584, Korea, Republic of
Site KR82013
Goyang Gyeonggido, 10408, Korea, Republic of
Site KR82008
Namdong Incheon Gwang'yeogsiv, 405 7, Korea, Republic of
Site KR82003
Hwasungun Jeonranamdo, 58128, Korea, Republic of
Site KR82012
Seoul Seoul Teugbyeolsi, 06351, Korea, Republic of
Site KR82006
Busan , 49241, Korea, Republic of
Site KR82009
Seoul , 120-7, Korea, Republic of
Site PL48001
Olsztyn Warmińsko-mazurskie, 10-22, Poland
Site PL48002
Bydgoszcz , 85-16, Poland
Site PL48007
Poznan , , Poland
Site PT35106
Coimbra , 3000, Portugal
Site PT35101
Porto , 4200-, Portugal
Site RO40005
București , , Romania
Site RS38102
Belgrade , 11000, Serbia
Site ES34009
Vitoria Alava, 01009, Spain
Site SE46003
Stockholm Stockholms Lan, 171 7, Sweden
Site SE46002
Lund , 221 8, Sweden
Site TW88605
Kaohsiung , 112, Taiwan
Site TW88604
Kaohsiung , 83301, Taiwan
Site TW88603
Taipei , 114, Taiwan
Site GB44007
Exeter Devon, EX2 5, United Kingdom
Site GB44019
Plymouth Devon, PL6 8, United Kingdom
Site GB44006
Cottingham East Riding Of Yorkshire, HU165, United Kingdom
Site GB44018
London London, City Of, WC1E , United Kingdom
Site GB44002
Birmingham , B95SS, United Kingdom
Site GB44015
Cardiff , CF4 4, United Kingdom
Site GB44020
Leeds , LS9 7, United Kingdom
Site GB44004
Nottingham , NG5 1, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 2

Estimated Enrollment:

98

Study ID:

NCT02927262

Recruitment Status:

Completed

Sponsor:


Astellas Pharma Global Development, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.